Medicine by the Numbers

A Collaboration of TheNNT.com and AFP

Metformin for Improving Maternal and Infant Outcomes in Pregnant Women Who Are Obese

 

Am Fam Physician. 2019 Mar 1;99(5):online.

image

 Enlarge     Print

METFORMIN USE IN PREGNANT WOMEN WHO ARE OBESE

BenefitsHarms

No infants were prevented from being born large for gestational age

1 in 6 women experienced diarrhea

METFORMIN USE IN PREGNANT WOMEN WHO ARE OBESE

BenefitsHarms

No infants were prevented from being born large for gestational age

1 in 6 women experienced diarrhea

Details for This Review

Study Population: Pregnant women who are obese (defined as first trimester or prepregnancy body mass index [BMI] of at least 30 kg per m2) who do not have preexisting diabetes mellitus or polycystic ovary syndrome

Efficacy End Points: Decrease in the risk that infants will be large for gestational age, defined as greater than 90th percentile for gestational age and sex

Harm End Points: Adverse events associated with medication, most notably diarrhea

Narrative: More than one-half of pregnant women in the United States are overweight or obese. Infants born to these women are at increased risk of prematurity, hypoglycemia, respiratory distress at birth, admission to the neonatal intensive care unit, stillbirth, congenital anomalies, macrosomia with possible birth injury, and childhood obesity. Overweight and obese women are also at increased risk of complications during pregnancy.1 Metformin, an inexpensive medication used to treat type 2 and gestational diabetes, improves insulin sensitivity by decreasing hepatic glucose production and increasing peripheral uptake and use of glucose. Women who are overweight or obese have increased insulin resistance, which exposes the developing fetus to higher levels of blood glucose over time and contributes to excessive fetal growth. Diet and lifestyle modifications have shown only modest effects in this population. Metformin use during pregnancy may increase insulin sensitivity, thereby decreasing the risk of maternal and fetal complications.2

A Cochrane review of three randomized controlled trials including 1,099 pregnant women in the United Kingdom and Alexandria, Egypt, compared metformin (initiation between 10 and 20 weeks' gestation and continuing

Author disclosure: No relevant financial affiliations.

References

1. American College of Obstetricians and Gynecologists. ACOG Committee opinion no. 549: obesity in pregnancy. Obstet Gynecol. 2013;121(1):213–217.

2. Dodd JM, Grivell RM, Deussen AR, Hague WM. Metformin for women who are overweight or obese during pregnancy for improving maternal and infant outcomes. Cochrane Database Syst Rev. 2018;(7):CD010564.

 

 

Copyright © 2019 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions

CME Quiz

More in AFP


Editor's Collections


Related Content


More in Pubmed

MOST RECENT ISSUE


Jun 15, 2019

Access the latest issue of American Family Physician

Read the Issue


Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article